NSN. Yu. Semigolovskii

N. Yu. Semigolovskii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


N. Yu. Semigolovskii has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sodium arginine succinate in elective PCI: a randomized trial of ischemia-reperfusion syndrome prevention

    by I.S. Simutis, N.YU. Semigolovskii, I.G. Lobachenko, M.S. Danilov, E.I. Guzovskiy, A.YU. Petrov

    Objective. To evaluate the effect of perioperative arginine sodium succinate infusion therapy on the incidence of ischemia-reperfusion syndrome (SIR) in patients with stable coronary artery disease (CHD) during elective percutaneous coronary intervention (PCI). Materials and methods. A single-center prospective, randomized, partially blind, open-label intervention study was conducted. The study included patients aged 60 years and older, regardless of gender, with a Charlson comorbidity index of at least 4 points. A total of 113 patients were screened, of which 9 were excluded according to the non-inclusion criteria and 16 according to the exclusion criteria. The final sample included 88 patients divided into two groups: the arginine sodium succinate group (n=43); the Ringer’s solution group (n=45). Infusion therapy in both groups was performed once at a dose of 10 ml/kg/day. The infusion started 30 minutes before PCI. The primary endpoint of the study is the incidence of SIR within 30 days after PCI. SIR was diagnosed based on a composite criterion, including: electrocardiography (ECG) data; echocardiography (EchoCG) results; laboratory markers of myocardial damage; thrombotic markers. It should be noted that limiting the sample to patients aged 60 years and older with a Charlson index >4 increases the risk of complications, which makes it possible to more clearly identify the potential preventive effect of cytoprotective therapy. At the same time, this approach severely limits the generalizability of the results obtained: the conclusions of the study cannot be directly extrapolated to younger age groups or patients with a lower comorbid load. Results. Perioperative use of arginine sodium succinate was associated with an almost twofold decrease in the incidence of SIR compared with Ringer’s solution, especially in patients with a SYNTAX Score of 8—15 points (p=0.040). Conclusion. The use of arginine sodium succinate was accompanied by a decrease in the incidence of SIR in patients who underwent elective PCI, which indicates the prospects of its use in the perioperative period. The results obtained should be considered as preliminary and requiring confirmation in large multicenter studies.

  • Sepsis and atrial fibrillation: the role of amiodarone, alternative strategies and metabolic therapy. A systematic review

    by I.S. Simutis, N.YU. Semigolovskii, E.A. Zelenaya, M.S. Danilov

    Objective. To analyze the role of amiodarone, alternative rhythm and rate control strategies, and metabolic therapy in sepsis-associated atrial fibrillation (AF). Methods. A systematic search was conducted in PubMed/MEDLINE, Embase, Cochrane Library, and RSCI up to January 2026. Randomized controlled trials (RCTs), prospective and retrospective cohort studies (n≥30), and controlled experimental studies in adults with sepsis/septic shock and supraventricular tachyarrhythmias were included. Additionally, RCTs of succinate-containing and metabolic therapies in other critical conditions (acute myocardial infarction, cardiac surgery, stroke, severe traumatic brain injury) evaluating arrhythmic or mechanistically relevant endpoints were considered. Results. New-onset AF in sepsis is associated with a 2- to 3-fold increase in mortality. Amiodarone effectively controls rhythm and rate but does not improve survival in septic shock and carries risks of negative inotropy, hypotension, torsade de pointes, and organ toxicity. In an RCT, propafenone provided faster cardioversion and fewer AF recurrences compared to amiodarone with similar mortality; a survival benefit was observed in patients without significant left atrial dilatation. Short-acting β1-blockers (esmolol, landiolol) safely control heart rate in hyperdynamic shock. Simultaneous correction of hypokalemia and hypomagnesemia increases the likelihood of spontaneous cardioversion. Succinate-containing infusions (Reamberin) and Cytoflavin in RCTs for critical illness reduce reperfusion arrhythmias and improve left ventricular systolic function. Discussion. Evidence supporting propafenone and β-blockers is derived from a limited number of RCTs with heterogeneous inclusion criteria. Data on metabolic therapy in sepsis-associated AF are extrapolated from studies in other critical conditions (AMI, COVID-19). Direct multicenter RCTs of succinate-based therapies with arrhythmic endpoints in sepsis are lacking. Conclusion. In sepsis-associated AF, amiodarone should be reserved for patients with significant structural heart disease and left atrial dilatation. Propafenone and short-acting β1-blockers are preferable alternatives in patients without substantial myocardial remodeling. Succinate-containing and metabolic therapy is pathogenetically justified as an organ-protective adjuvant but requires dedicated RCTs in the sepsis population. Funding source. The authors declare no external funding.

  • Open Access

    The relationship between peripheral vascular resistance and the level of physical activity in young adults with healthy weight and overweight

    by Yo. Kh.H. Hussein, I. Yu. Pchelin, N. Yu. Semigolovskii, V. N. Vasilkova, O. V. Soloviev

    Introduction. A sedentary lifestyle is considered an independent risk factor associated with cardiovascular disease morbidity and mortality. Aim. To assess the relationship between the level of physical activity (PA) and indicators of total peripheral vascular resistance (TPVR) in normal-weight and overweight young individuals. Mat erials and methods. The study included 79 patients aged 18–45 with no history of cardiovascular disease: 33 overweight and 46 normal-weight. In addition to standard data, we assessed TPVR using the APKO-8-RIC-M analyzer and PA using the IPAQ questionnaire. Statistical analysis was performed using the Student’s t-test for independent samples, the Pearson correlation coefficient (r), and linear regression. Results. There were no significant differences in TPVR and PA levels between the groups. When analyzing the indicators depending on patients’ sex, no significant differences were found in TPVR (p = 0.109) and IPAQ scores (p = 0.956). In individuals with normal body weight, the level of physical activity was negatively correlated with age (r = -0.302, p = 0.041), total cholesterol (r = -0.352, p = 0.017) and glucose (r = -0.329, p = 0.026), but did not correlate with TPVR. In the overweight group, no relationships with age and biochemical parameters were found, but an inverse correlation was observed between IPAQ and TPVR (r = -0.385, p = 0.027). Linear regression showed a significant relationship between TPVR and physical activity (p = 0.027), which explained 14.9% of the variance in TPVR. Conclusion. A low level of physical activity might have a negative impact on the functional state of the cardiovascular system of young overweight individuals, regardless of its impact on body weight and biochemical parameters.

  • Open Access

    Atrial fibrillation in sepsis and the potential effects of propafenone and levocarnitine

    by N. Yu. Semigolovskii, S. O. Mazurenko, L. G. Ermolaeva, E. V. Balukova, S. N. Semigolovskii, Н. Ю. Семиголовский, С. О. Мазуренко, Л. Г. Ермолаева, Е. В. Балукова, С. Н. Семиголовский

    Actually sepsis is one of the most important health problems, as the incidence of it in the world is high and continues to grow, and mortality reaches 40–60%, especially with the development of septic shock. Frequent heart damage in sepsis – septic cardiomyopathy (an established term for sepsis-caused by acute cardiac dysfunction syndrome unrelated to ischemia due to damage to the coronary arteries) – is often complicated by the occurrence of cardiac arrhythmias. Ventricular arrhythmias are rare, and atrial fibrillation develops in 20–30% of cases, reaching 45% with septic shock. At the same time, mortality increases by about 2–3 times if attempts at cardioversion are unsuccessful. However, the issues of antiarrhythmic therapy have not yet been regulated. The Russian and Eurasian clinical guidelines for the treatment of atrial fibrillation (2025) do not mention sepsis. And the recommendations of the European Society of Cardiology and the Association of Cardiothoracic Surgeons (2024), supplemented by the European Heart Rhythm Association (2025), only state that sepsis is a trigger for atrial fibrillation and a risk factor for its subsequent recurrence in almost half of the discharged patients with sepsis, and the degree of inflammation correlates with the frequency of its development and recurrence. Drugs commonly used for cardioversion – beta-blockers, calcium antagonists, amiodarone – can worsen the situation, negatively affecting the hemodynamics of septic patients, especially in shock. The culprits of the hipotensive effect of amiodarone, in particular, are due of the emulsifier polysorbate-80 and benzyl alcohol in its composition. Based on an analysis of current clinical studies and our own clinical experience, the article examines the use of propafenone in this case, devoid of cardiodepressive properties. It is also advisable to use levocarnitine adjuvantly, which has positive inotropic and antioxidant properties, as well as being able to resist inflammatory and proarrhythmic links in the pathogenesis of sepsis, and prevent recurrence.

  • L-Arginine as a New Tool in the Intensive Care of Cardiovascular Disorders: Review

    by I.S. Simutis, N.YU. Semigolovskii, I.G. Lobachenko, A.A. Sapegin, M.S. Danilov, E.S. Iusupov, T.N. Enkina, K. Blitsyn, I.E. Karpov, I.V. Suvorova

    Relevance. Cardiovascular diseases (CVDs) remain one of the leading causes of mortality worldwide. In recent years, significant attention has been given to L-arginine, a conditionally essential amino acid that serves as a key precursor of nitric oxide, a critically important mediator of vascular function. Dysregulation of L-arginine metabolism and the development of endothelial dysfunction play a significant pathogenetic role in the development and progression of CVDs. Objective. This review aims to systematize current data on the role of L-arginine in the regulation of vascular tone, its impact on endothelium-dependent vasodilation, and to assess the potential application of L-arginine in the intensive care of cardiovascular diseases. Material and methods. A comprehensive analysis of the results of in vitro and in vivo experimental studies, as well as clinical trials focused on examining the influence of L-arginine on endothelial function, hemodynamic parameters, coronary blood flow, and other cardiovascular system parameters was conducted. Particular attention was given to analyzing the molecular mechanisms of NO-mediated action of L-arginine and its interaction with the arginase enzyme. Results. L-arginine contributes to enhancing endothelium-dependent vasodilation, reducing blood pressure, and can have a positive impact in cases of coronary heart disease, heart failure, and atherosclerosis. It is important to note that the effectiveness of L-arginine therapy can be modulated by the level of ADMA, an endogenous inhibitor of nitric oxide synthase (NOS). Conclusion. L-arginine represents a promising therapeutic agent for use in the intensive care of CVDs, especially in patients facing potential ischemia-reperfusion syndrome. To determine optimal therapeutic strategies, including dosage selection and identification of target patient groups, further large-scale, placebo-controlled clinical studies are necessary.

  • Low-carbohydrate diets in diabetes mellitus: A clinical case report and a brief literature review

    by N. V. Khudyakova, I. S. Khudiakov, I. Yu. Pchelin, S. Stojanovich, D. Radoičić, N. Yu. Semigolovskii, S. O. Mazurenko, V. V. Smirnov

    Despite the numerous groups of hypoglycaemic drugs available, disability and mortality from complications of diabetes mellitus (DM) are increasing every year. This requires new effective approaches to the management of patients with DM. One of these approaches is diet therapy. Diet is considered the most important component of DM treatment by all authoritative organisations. Before the discovery of insulin, carbohydrate-restricted diets were widely used for DМ, but recently, leading publications have reported that dietary correction with carbohydrate restriction is required without clear guidelines on the extent of such restriction, and the focus is mainly on drug treatment. Analysis of the literature confirms the positive effect of low-carbohydrate diets (LCD) on weight loss, improvement of the glycaemic profile in DМ, and reducing the number and doses of hypoglycaemic drugs, but it remains unclear which diet to choose in a certain situation, which one will give the best results and be safe in the short and long term. Studies on this issue have been conducted, but their results are contradictory. To date, there is no consensus on which LCD diet is the optimal solution for DМ. The article describes a clinical case of four months treatment of LCD with moderate carbohydrate intake and its effect on weight, metabolic parameters, and hypoglycaemic therapy in a patient with long-term DM, corrected with insulin therapy for the last 10 years. This diet, combined with the patient’s high compliance, led to an 11-kilogram weight loss, improved carbohydrate metabolism and withdrawal from insulin therapy, as well as helped normalise blood pressure without the treatment of antihypertensive drugs and improved kidney function.

  • Cardioprotection method for percutaneous coronary interventions in elderly patients with acute coronary syndrome

    by N. Yu. Semigolovskii, I. G. Semenova, A. V. Kozaev, A. B. Guslev, S. O. Mazurenko, T. T. Berdikulova

    Introduction . Acute coronary syndrome (ACS) is the main cause of death in elderly patients who suffer worse from percutaneous coronary interventions (PCI), and new cardioprotection techniques are in high demand. Aim . To study the efficacy of levocarnitine in preventing complications due to PCI in elderly patients with acute coronary syndrome. Materials and methods . 80 ACS patients were randomized into 2 groups of 40 people: the main group was the average age of 78 (75, 93), received 1.0 g of levocarnitine intracoronary, followed by an intravenous infusion of 2.0 g/day for 3 days; and the control group of age 77 (75, 91) received placebo administration. PCI was performed an average of 3.5 hours after the onset of ACS symptoms. The MB fraction of creatine phosphokinase (CPK-MV) and highly sensitive troponin I (hsTrI), ECG and EchoCG parameters in dynamics, course and outcomes were determined. Results . The dynamics of biomarker levels was more favorable in the main group, where there was a smaller increase in hsTrI at 1 day after PCI and an accelerated decrease at 3 day after PCI. CPK-MB on day 3 in the main group was significantly lower than the control level (p < 0.001). The significantly lower average left ventricular ejection fraction in the main group initially (p < 0.023) significantly exceeded the control level on day 3 after PCI (p < 0.001). There was a faster positive dynamics of the ECG and a tendency to decrease the frequency of arrhythmic episodes in the main group compared with the control group. There was no hospital mortality in the main group, and it was 10.0% in the control group. Conclusions . The described technique of adjuvant cardioprotection in PCI appears to be an available, effective and safe addition to the standard provision of reperfusion in elderly patients with ACS.

  • Analytical review of the pathophysiological mechanisms of ischemia-reperfusion syndrome development in PCI

    by I.S. Simutis, I.G. Lobachenko, N.YU. Semigolovsky, M.S. Danilov, E.S. Yusupov, J.V. Suvorova, A.A. Sapegin, S.V. Lytochkina, A.YU. Yakovlev

    Introduction. Despite the known risks of myocardial damage as a result of reperfusion, current treatment strategies often focus only on immediate recanalization of the coronary arteries. At the same time, a lot of experimental and clinical data confirms that this procedure can provoke additional ischemic reperfusion injury to the myocardium. Objective. Analysis of the existing literature on ischemia-reperfusion syndrome in percutaneous coronary intervention in order to systematize knowledge about the mechanisms of its development. Material and methods. The study was conducted in collaboration with international organizations to analyze PRISMA (Preferred Reporting Articles for Systematic Reviews and Meta-analyses). The search for users was conducted in the PubMed, Google Scholar, and eLibrary.ru. Results. A total of 4.268 initial results were found, including PubMed — 2.134 publications, Google Scholar — 1.280 and eLibrary.ru — 854 publication. Only 1.523 papers turned out to be relevant, after studying which only 70 full-text publications were selected for the review, which met all the selection criteria and were included in the analysis. Most studies describe the pathophysiological mechanisms contributing to the development of ischemia-reperfusion syndrome during percutaneous coronary intervention. Conclusion. Ischemia-reperfusion syndrome causes activation of various pathophysiological mechanisms, among which endothelial dysfunction, oxidative stress, inflammatory response, and energy exchange disorders play a leading role. This is the basis for the development of new therapeutic strategies to prevent myocardial damage during percutaneous coronary interventions and improve treatment outcomes in patients with coronary artery disease.

  • Effect of perioperative fluid therapy on ischemia-reperfusion syndrome in elective percutaneous coronary interventions

    by I.S. Simutis, N.Yu. Semigolovsky, M.S. Danilov, I.G. Lobachenko, E.S. Yusupov, Yu.V. Suvorova, V.A. Gostimsky, T.N. Enkina

    Objective. To evaluate the incidence of ischemia-reperfusion syndrome (IRS) in elective percutaneous coronary interventions (PCI) in patients with stable coronary artery disease (CAD). Material and methods. A prospective, single-center, randomized study was conducted. The study included 60 patients older than 60 years with stable coronary artery disease with involvement of two or more vessels who underwent elective PCI. The patients were randomized into two groups: a control group that received Ringer’s solution and a test group that received Reamberin solution. Both solutions were administered at a dose of up to 10 mL/kg/day in the preoperative period with a transition to a maintenance infusion daily with a volume corresponding to physiological requirements. The patients were assessed at five timepoints (before surgery, 3 hours after surgery, Day 1, Day 14, and Day 30 after surgery). The key criteria included the duration of hospital stay, complications (arrhythmias, thrombotic events, cardiovascular failure), and the trends in laboratory and instrumental parameters (echocardiography, electrocardiography, troponin, and creatine phosphokinase-MB levels), as well as risk factors for the IRS. Results. The perioperative prophylactic use of Reamberin solution significantly reduced the IRS incidence to 44.1% vs. 73.0% in the control group (p<0.05). In the test group, no significant associations were found between the level of predictors (the number of implanted stents, the Charlson Comorbidity Index) and the IRS risk. No significant intergroup differences in clinical outcomes and complication rates between groups were observed. Conclusion. The perioperative use of the succinate-containing drug, Reamberin, for elective PCIs is associated with a significant decrease in the frequency and severity of IRS manifestations. Further research is needed to clarify the mechanisms of protective action, doses, and dosage regimens.


  • Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coronary intervention

    by N.YU. Semigolovskiy, I.G. Lobachenko, I.S. Simutis, M.S. Danilov, E.S. Yusupov, V.A. Ratnikov, T.N. Enkina, M.A. Stelyukova

    Objective. To study modern strategies for pharmacological treatment and prevention of reperfusion-ischemia syndrome in percutaneous coronary intervention. Material and methods. Literature data were searched in the PubMed, Google Scholar and eLibrary databases.EN in accordance with PRISMA principles (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Results. We found numerous strategies for treatment and prevention of reperfusion-ischemia syndrome in percutaneous coronary intervention. However, there is no a single technique ensuring absolute effectiveness. Various approaches, such as antioxidants, medications improving microcirculation and even innovative methods are actively being developed. However, their results can vary depending on characteristics of patients, degree of ischemia and other concomitant factors. Conclusion. The number of clinical studies devoted to cardiac protection during percutaneous coronary intervention significantly increased in recent years. This indicates high interest of medical community in the study of reperfusion-ischemia syndrome.